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Abstract
Introduction: There has been increased interest in the objective monitoring of free-living walking behavior using
accelerometers in clinical research involving persons with multiple sclerosis (MS). The current investigation examined and
compared the accuracy of the StepWatch activity monitor and ActiGraph model GT3X+ accelerometer for capturing steps
taken during various speeds of prolonged, over-ground ambulation in persons with MS who had mild, moderate, and
severe disability.
Methods: Sixty-three persons with MS underwent a neurological examination for generation of an EDSS score and
undertook two trials of walking on the GAITRite electronic walkway. Participants were fitted with accelerometers, and
undertook three modified six-minute walk (6MW) tests that were interspersed with 10–15 minutes of rest. The first 6MW
was undertaken at a comfortable walking speed (CWS), and the two remaining 6MW tests were undertaken above (faster
walking speed; FWS) or below (slower walking speed; SWS) the participant’s CWS. The actual number of steps taken was
counted through direct observation using hand-tally counters.
Results: The StepWatch activity monitor (99.8%–99.9%) and ActiGraph model GT3X+ accelerometer (95.6%–97.4%) both
demonstrated highly accurate measurement of steps taken under CWS and FWS conditions. The StepWatch had better
accuracy (99.0%) than the ActiGraph (95.5%) in the overall sample under the SWS condition, and this was particularly
apparent in those with severe disability (StepWatch: 95.7%; ActiGraph: 87.3%). The inaccuracy in measurement for the
ActiGraph was associated with alterations of gait (e.g., slower gait velocity, shorter step length, wider base of support).
Conclusions: This research will help inform the choice of accelerometer to be adopted in clinical trials of MS wherein the
monitoring of free-living walking behavior is of particular value.
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Introduction
There has been increasing interest in approaches for objectively
monitoring the status of persons with multiple sclerosis (MS) under
real-world conditions [1–3]. This interest has highlighted the
potential value of objectively monitoring free-living walking
behavior using accelerometers in clinical research involving
persons with neurological diseases including MS [1–3]. Acceler-
ometers are motion sensors worn on the body (e.g., around the
waist or ankle) during the waking hours of the day and over a
representative sampling period (e.g., seven days). The devices
capture and record the total amount of walking undertaken in
free-living conditions based on the metric of steps taken per day
(steps/day). The number of steps/day reflects a straight-forward
metric of the overall amount of walking undertaken during one’s
everyday life (i.e., free-living walking behavior) [3,4] and is a
marker of health and disability status in MS [5–7]. There are some
devices that provide measures of walking speed (e.g., ActiBelt; [8]),
but this metric is not easily interpretable by researchers, clinicians,
and patients. There further are guidelines for easily interpreting
steps/day [9], but this is not the case for walking speed.
Acceleration counts represent another possible metric for quan-
tifying ambulation, but such a metric does not have much meaning
for clinicians and patients.
Importantly, the successful application of accelerometers for
measuring free-living walking behavior depends on selecting a
device with acceptable accuracy for capturing steps taken during
ambulation in persons with MS. Such an assessment of accuracy
should be established under controlled conditions (i.e., laboratory
settings) before investing considerable time and resources into an
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investigation under more ecologically valid conditions. The
assessment of accuracy is important as the gait patterns of persons
with neurological diseases such as MS can present challenges for
devices that measure steps or strides during ambulation [10]. To
date, there are two published investigations regarding the accuracy
of accelerometers for capturing steps taken during ambulation in
persons with MS [4,11]. One study reported that an ActiGraph
accelerometer (model 7164) worn around the waist accurately
measured steps taken while walking on a treadmill for 6 minutes at
2.5 (99.8% accuracy rate) and 3.0 (99.7% accuracy rate) mph in
24 adults with mild MS; there was minimal inaccuracy (4.1% error
rate or 95.9% accuracy rate) while walking at 2.0 mph [4].
Another study reported that the StepWatch Activity Monitor worn
around the ankle accurately measured strides (98.1% accuracy
rate) compared with a GaitMat II in 20 persons with Parkinson’s
disease and MS during 3.87 meters of self-paced, over-ground
walking [11]. There have been no published reports of direct
comparisons of accelerometer accuracy for capturing steps taken
during prolonged periods of over-ground walking across the
spectrum of MS disability status.
One approach for measuring the accuracy of accelerometers for
detecting steps during over-ground walking involves the systematic
manipulation of speed during consecutive 6-minute walk (6MW)
tests. The 6MW has been considered a proxy of community
ambulation in MS [7,12] and persons with Expanded Disability
Status Scale (EDSS) scores between 0 and 6.5 can perform
repeated 6MW tests [13]. Indeed, previous research has delivered
three, over-ground 6MW tests to successfully manipulate speed
and examine the O2 cost of walking in persons with MS [14,15].
In those studies, one 6MW was performed at the participant’s
comfortable walking speed (CWS), whereas the other two 6MW
tests were undertaken above (faster walking speed; FWS) and
below (slower walking speed; SWS) the participant’s CWS [14,15].
Such an approach might be advantageous for an examination and
comparison of accelerometer accuracy across different conditions
of ambulation and levels of disability.
The current investigation examined and compared the accuracy
of the StepWatch activity monitor and ActiGraph model GT3X+
accelerometer for capturing steps taken during various speeds of
prolonged, over-ground ambulation in a sample of persons with
MS who had mild, moderate, and severe disability. This extends
the ecological validity of accelerometer accuracy trials from a
treadmill walking protocol (e.g., [4]) to an over-ground walking
protocol, prior to examining accuracy under free-living conditions.
This is an intermediary condition between the treadmill and real
world, and reflects the progression of confirmation before testing
under real-world conditions. Importantly, this study included
commercially-available ActiGraph and StepWatch devices, as
these are the most commonly used accelerometers for measuring
ambulation in healthy and disease populations, including MS [10].
Methods
Participants
Prospective participants residing in the local community (i.e.,
within 60 minutes of our laboratory) were contacted by a flyer that
was distributed amongst participants from previously conducted
studies in our laboratory. Prospective participants were further
recruited via telephone and e-mail messages along with referrals
from a local neurologist. Those who expressed interest in the study
underwent a screening for inclusion criteria that included a
neurologist-confirmed diagnosis of MS, relapse free during the
previous 30 days [16], ambulatory with or without assistance, age
between 18 and 65 years, and absence of risk-factors for
undertaking strenuous physical activity (e.g., cardiovascular
diseases, diabetes, hyperlipidemia, and hypertension). As we were
interested in forming groups of mild, moderate, and severe
disability, prospective participants underwent a self-reported
EDSS [17] over the telephone. The resultant score was not used
in data analyses, but was used as a preliminary indicator of
disability status for the purpose of recruiting disability subgroups of
relatively equal size. As an inclusion criterion involved being
ambulatory, we recruited persons with MS who had a maximum
EDSS score of 6.5 (i.e., constant bilateral assistance). An EDSS
score of 7.0 (i.e., the next level of disability) reflects the inability to
walk with an assistive device for more than 5 meters, and reflects
being regularly wheelchair-bound. We felt that it would not be
possible to examine and compare accelerometer accuracy for
detecting steps taken by including persons with this severe a level
of disability. We contacted 148 persons with MS, and 61 were
uninterested in participating. The resulting 87 persons underwent
screening, and 15 qualified for the study, but were unable to travel
to our laboratory, and 9 persons were disqualified based on the
presence of risk-factors for undertaking physical activity. The final
sample consisted of 63 persons with MS.
Accelerometers
Steps taken during the 6MW tests were measured by an
ActiGraph model GT3X+ accelerometer (Health One Technol-
ogy, Fort Walton Beach, FL) and a StepWatch Activity Monitor
(Orthocare Innovations, Mountlake Terrace, WA). The Acti-
Graph model GT3X+ contains a solid state, digital accelerometer
that generates an electrical signal proportional to the force acting
on it along three axes. The acceleration signal is sampled by a 12-
bit analog-to-digital converter and stored in a raw format in the
units of gravity (G’s). The raw activity data are post-processed in
ActiLife 6 software and are expressed as step counts; this study
only included step counts for consistency with the StepWatch. The
StepWatch activity monitor is a microprocessor-controlled, two-
dimensional accelerometer that measures step counts and step
rates per unit time. The threshold for acceleration is stored in the
unit’s memory in G’s and is calibrated by the manufacturer
(Orthocare Innovations, Mountlake Terrace, WA); the threshold
for all units in the current study was 1.08 G’s.
The ActiGraph was worn on an elastic belt around the waist
and above the right hip, whereas the StepWatch was worn on an
elastic strap around the ankle above the right lateral malleolus, as
per manufacturer recommendations. The epoch (i.e, sampling
window) for both the ActiGraph and StepWatch was 3 seconds
(i.e., this is the shortest epoch available for the StepWatch). The
short epochs were chosen for flexibility in data processing and
precise linking with the exact beginning and end of the 6MW tests.
The data from both accelerometers were imported into Microsoft
Excel for processing. We used five separate ActiGraph model
GT3X+ accelerometers and five separate StepWatch activity
monitors in the study, and counterbalanced the application of each
of these units, such that each individual accelerometer was used at
least 3 times within each disability status group. We further
checked the accuracy of all accelerometers for capturing 1000
steps while walking on a treadmill at 3.0 mph using laboratory
personnel before beginning the research and upon its completion;
this ensured proper functioning of the devices before and after the
research protocol. The ActiGraph model GT3X+ was initialized
using the low-frequency extension feature, in order to increase the
accelerometer’s sensitivity for capturing low frequency accelera-
tions (i.e., slow walking). We further set the StepWatch activity
monitor to flash for the first 50 steps taken to ensure functionality
prior to the first 6MW. To do this, once properly fitted with the
Steps Taken among Persons with MS
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StepWatch, we instructed the participant to take 10 steps prior to
the first 6MW administration to verify that the unit was indeed
flashing and thus measuring steps taken.
Disability status
All participants underwent a neurological exam by a Neuro-
status certified examiner who generated EDSS scores [18] for
describing the sample and stratifying persons into three groups
based on mild (EDSS of 0–3.5; n = 20), moderate (EDSS of 4.0–
5.5; n = 24), and severe (EDSS of 6.0–6.5; n = 19) disability status.
Walking/gait outcomes
Walking and gait measures were included for identifying
possible sources of error in accelerometer output. The MSWS-
12 is a 12-item, patient-rated measure of the impact of MS on
walking-related activities (including walking, running, standing,
climbing stairs) [19]. The items are rated on a 5-point scale of 1
(Not at all) to 5 (Extremely), and the items represent limitations of
walking during the past 2 weeks. The MSWS-12 is scored by
summing the item scores, subtracting 12, dividing the difference by
48, and then multiplying the result by 100. The final score ranges
between 0 and 100 and higher scores are indicative of worse
walking. The MSWS-12 has good evidence for its internal
consistency, test-retest reliability, longitudinal invariance, and
validity of scores as a measure of walking mobility in MS [20].
Participants completed two trials of walking on a 16-foot
GAITRite (CIR systems, Inc) electronic walkway at a comfortable,
self-selected pace for measuring gait outcomes. We recorded the
functional ambulation profile (FAP) score, velocity (cm/sec),
cadence (steps/min), step length (cm), step time (sec), base of
support (cm), and double support (%). We averaged the recorded
values per variable across both trials for improved reliability.
Ethics Statement
The procedure was approved by the University of Illinois at
Urbana-Champaign Institutional Review Board and all partici-
pants provided written informed consent before beginning the
study.
Protocol
Participants completed a demographic questionnaire and the
MSWS-12, followed by a neurological examination for generation
of an EDSS score. Participants then undertook two trials of
walking on the GAITRite electronic walkway. One researcher
then guided each participant through the course for the 6MW tests
as a familiarization protocol. The course was located in an
accessible, rectangular hallway that was clear of obstructions and
foot traffic. The StepWatch and ActiGraph accelerometers were
then properly positioned on each participant. Participants
completed the three 6MW tests that were interspersed with 10–
15 minutes of rest. The first 6MW test involved the participant’s
CWS, and the two remaining 6MW tests were undertaken above
(FWS; +0.5 mph of CWS) or below (SWS; 20.5 mph of CWS) the
participant’s CWS; the order of the FWS and SWS 6MW tests
were counterbalanced. During the CWS 6MW test, one
researcher followed the participant and recorded the total distance
walked using a measuring wheel (Keson MP301, Aurora, IL),
which was further outfitted with a pre-calibrated bicycle computer
(Cateye Velo5, Osaka, Japan). Based on the total distance walked
and time (i.e., 6 minutes), average speed for CWS was calculated
in miles per hour (mph) using Microsoft Excel. The manipulation
of walking speed in the 2nd and 3rd 6MW tests was accomplished
by having the participant follow a researcher who controlled the
walking pace using the Keson measuring wheel outfitted with the
bicycle computer; we recorded total distance and using time,
computed average speed as a manipulation check [14,15]. For all
three 6MW tests, the actual number of steps taken was further
counted by a laboratory research assistant through direct
observation using a hand-tally counter. We recognize that having
the participants follow a researcher during FWS and SWS
conditions involves a dual-task of walking and the participant
cognitively adapting the pace of his/her walking to that of the
researcher. This might bias 6MW distance and could be a major
confound for comparing 6MW distance values herein with other
studies. Nevertheless, this protocol was necessary for manipulating
the speed of over-ground walking in order to test the accuracy of
the accelerometers under different walking conditions. The
current 6MW distance values are not comparable to those from
studies that use a standard 6MW protocol. Participants received
$25 remuneration upon completion of the study.
Data Analysis
The data analyses were performed using IBM SPSS Statistics,
Version 21 (SPSS Inc., Chicago, IL) and the data are available
upon written request and approval by the University of Illinois.
Descriptive data are presented as mean scores (standard deviation;
SD), unless otherwise noted. Step counts measured by the
accelerometers are expressed as a percentage of the actual number
of steps taken measured by direct observation during each of the
6MW tests (i.e., device accuracy). That was the primary dependent
variable and values less than 100% reflect underestimation of step
counts by the accelerometer, whereas values greater than 100%
reflect overestimation of step counts by the accelerometer. We first
conducted a 3 (Condition: CWS, FWS, and SWS)63 (Group:
mild, moderate, and severe) mixed-model ANOVA on the
outcome of walking speed. Condition was a within-subjects factor,
and group was a between-subjects factor. This analysis served as a
manipulation check of our protocol across the three walking
conditions and disability levels. We then conducted a 2 (Device:
StepWatch and ActiGraph)63 (Speed: CWS, FWS, SWS)63
(Group: mild, moderate, and severe) mixed-model ANOVA on the
outcome of device accuracy. Device and condition were within-
subjects factors, and group was a between-subjects factor. This
analysis examined differences in the accuracy of the devices overall
and as a function of speed and disability status. We did not correct
for alpha because our a priori data analysis plan involved
examining accelerometer accuracy in two devices among three
disability groups. Finally, we were interested in walking and gait
outcomes (e.g., MSWS-12, GAITRite variables, and assistive
device use during the 6MW tests) as potential influences on any
inaccuracy in measurement. Thus, we examined the correlations
between walking/gait outcomes and accuracy of measurement of
the device/speed combination that measured the lowest percent-
age of actual steps taken (i.e., the greatest inaccuracy in




Demographic, clinical, and walking/gait characteristics of the
sample based on disability status are presented in Table 1. Briefly,
we enrolled 63 persons with a definite diagnosis of MS. The
sample was largely female (n = 48 or 76%) with an average age of
50.7 (9.2) years. Regarding clinical course of MS, 50 (79%) of the
participants had relapsing-remitting MS and 12 (19%) had
progressive MS; 1 participant had an unknown clinical course.
Steps Taken among Persons with MS
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The mean duration of MS (i.e., time since diagnosis) was 12.8 (8.5)
years, and median EDSS score was 4.0 with a range of scores
between 1.0 (i.e., minimal disability) and 6.5 (i.e., constant use of
bilateral assistance during walking) (IQR = 2.5). Overall, most
participants (i.e., 40/63; 64%) did not require the use of an
assistive device during the 6MW tests; 13 participants (21%) used a
cane, and 10 (16%) used a rollator. The current sample had
walking/gait characteristics that were similar to other samples of
persons with mild, moderate, and severe disability [21].
Speed Manipulation Check
All 63 participants completed the three 6MW tests without
stopping or obvious difficulty. Average speeds for the CWS, FWS,
and SWS 6MW tests in the overall sample and by subsamples with
mild, moderate, and severe MS are reported in Table 2. The
ANOVA indicated a significant main effect for speed (F(2,
120) = 477.32, p,.001, eta-squared = 0.89) supporting our suc-
cessful manipulation of speed across the 6MW tests. There further
was a significant main effect for disability (F(2, 60) = 47.09, p,
.001, eta-squared = .61) indicating that actual speed (and ulti-
mately distance) differed between mild, moderate, and severe MS.
The manipulation of speed did not differ as a function of disability
status based on a non-significant speed6disability interaction (F(4,
120) = 1.92, p = .11, eta-squared = .06).
Device Accuracy
Table 3 presents actual steps taken during the 6MW tests and
those measured by the ActiGraph and StepWatch in the overall
sample and per disability group. Table 3 further expresses these
data as percentage of actual steps taken measured by each device.
Results from the primary analysis for comparing accuracy (i.e.,
percentage of the actual number of steps taken) per device as a
function of speed and disability status are as follows. There was not
a significant device6speed6disability interaction (F(4, 120) = 1.14,
p = .34, eta-squared = .04), indicating that there was not a
difference in accuracy between the ActiGraph and StepWatch
across speed as a function of disability. The accuracy of devices did
not vary as a function of speed based on a non-significant
device6speed interaction (F(2, 120) = 0.27, p = .76, eta-
squared = .01). There further was a non-significant device6disa-
bility interaction (F(2, 60) = 2.58, p = .08, eta-squared = .08)
indicating that accuracy of the ActiGraph and StepWatch did
not significantly differ across disability groups. There was a
significant speed6disability interaction (F(4, 120) = 2.40, p = .05,
eta-squared = .07) indicating that there was a greater inaccuracy
(i.e., smaller percentage of actual steps taken measured by the
accelerometers) as a function of speed per level of disability, such
that inaccuracy was greatest in those with severe disability under
the SWS condition. There was a significant main effect for device
(F(1, 60) = 5.27, p = .03, eta-squared = .08) indicating that, overall,
the StepWatch was slightly more accurate than the ActiGraph
model GT3X+ accelerometer.
We performed an additional exploratory analysis of device
accuracy within groups based on ‘‘normal’’ walking speed. As
such, post-hoc, we re-categorized persons into three groups based
on normal walking speed recorded from the GaitRite (i.e.,
stratified as ‘community walkers’, ‘limited community walkers’,
and ‘community walkers’; [22,23]). Using those groups, there was
a statistically significant speed6group interaction (p = .01) on
device accuracy (i.e., percentage of actual steps taken measured by
the devices) indicating that there was a greater inaccuracy (i.e.,
smaller percentage of actual steps taken measured by the devices)
as a function of speed (i.e., CWS, FWS, SWS) per group, such that
inaccuracy was greatest in those classified as ‘most limited
community walkers’ under SWS conditions. There further was a
significant device main effect (p = .02) such that, overall, the
StepWatch measured a greater percentage of actual steps taken
than the ActiGraph model GT3X+ accelerometer. Collectively,
this pattern of results when examining groups based on normal
Table 1. Demographic, Clinical, and Walking/Gait Characteristics of 63 persons with mild, moderate, and severe MS.
Variable Overall (n = 63) Mild (n = 20) Moderate (n = 24) Severe (n = 19)
Age (years) 50.68 (9.22) 48.25 (10.68) 52.71 (7.97) 50.68 (8.91)
Sex (n, % female) 48/63 (76.2%) 14/20 (70.0%) 19/24 (79.2%) 15/19 (78.9%)
MS Duration (years) 12.83 (8.50) 10.80 (7.71) 14.58 (7.39) 12.74 (10.38)
MS Type (n,% RRMS) 50/63 (79.4%) 20/20 (100%) 18/23 (75.0%) 12/19 (63.2%)
EDSS (median, range) 4.0 (1.0–6.5) 3.0 (1.0–3.5) 4.0 (4.0–5.0) 6.0 (6.0–6.5)
6MW AD-None (n, %) 40/63 (63.5%) 19/20 (95.0%) 20/24 (83.3%) 1/19 (5.3%)
6MW AD-Cane (n, %) 13/63 (20.6%) 1/20 (5.0%) 4/24 (16.7%) 8/19 (47.4%)
6MW AD-Rollator (n, %) 10/63 (15.9%) 0/20 (0.0%) 0/24 (0.0%) 10/19 (52.6%)
FAP 87.32 (15.4) 96.42 (3.2) 92.42 (6.4) 71.79 (19.1)
Gait Velocity (cm/sec) 100.43 (30.1) 125.05 (18.6) 106.45 (21.2) 68.21 (19.1)
Cadence (steps/min) 101.19 (16.0) 110.25 (8.5) 106.99 (11.0) 84.82 (15.2)
Step Length (cm) 58.72 (11.3) 68.10 (8.2) 59.53 (8.4) 48.33 (8.2)
Step Time (sec) 0.64 (0.18) 0.55 (0.04) 0.57 (0.06) 0.81 (.23)
Base of Support (cm) 12.06 (4.2) 11.08 (3.0) 11.38 (2.9) 13.89 (6.0)
Double Support (%) 33.94 (14.5) 27.34 (4.1) 31.37 (4.4) 43.80 (22.7)
MSWS-12 40.57 (29.2) 11.98 (12.4) 41.58 (20.6) 72.79 (16.4)
Note: Data are presented as mean (SD) unless otherwise noted; 1 participant with moderate disability did not provide MS type; RRMS = Relapsing-remitting multiple
sclerosis; EDSS = Expanded Disability Status Scale; 6MW = 6-minute walk; AD = Assistive Device; FAP = Functional ambulation profile; MSWS-12 = Multiple Sclerosis
Walking Scale-12.
doi:10.1371/journal.pone.0093511.t001
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walking speed is entirely consistent with the device accuracy results
when analyzing the data based on disability status.
Associations Among Device Accuracy and Walking/Gait
Variables
We were interested in examining possible walking or gait-
related influences on the accuracy in measurement between device
types. This was unnecessary for the StepWatch because of its
accuracy in measurement under all walking conditions and for the
ActiGraph model GT3X+ under CWS and FWS conditions.
Accordingly, we only report the correlations between walking/gait
outcomes and the accuracy in measurement of the ActiGraph
model GT3X+ accelerometer under SWS conditions (i.e., the
speed and device combination with the greatest inaccuracy in
measurement). Bivariate correlations indicated that device accu-
racy (i.e., percentage of the actual number of steps measured) was
significantly associated with FAP scores (r = .361, p = .004), velocity
(r = .351, p = .005), step length (r = .376, p = .003), step time (r = 2
.352, p = .005), base of support (r = 2.255, p = .046), double
support (r = 2.356, p = .005), and MSWS-12 scores (r = 2.290,
p = .023). One-way ANOVA indicated that there were not
statistically significant differences in accuracy in measurement of
the ActiGraph model GT3X+ accelerometer based on the use of
an assistive device (i.e., none, cane, or rollator) during the 6MW
tests (F(2, 60) = 0.37, p = .69).
Discussion
The current investigation examined the accuracy of the
ActiGraph model GT3X+ accelerometer and the StepWatch
activity monitor for measuring steps taken during various speeds of
over-ground walking in persons with mild, moderate, and severe
Table 2. Average Speed under comfortable, fast, and slow walking conditions in 63 persons with mild, moderate, and severe MS.
Condition Disability Average Speed (mph)












Note: Data are presented as mean (SD); CWS = Comfortable walking speed; FWS = Faster walking speed; SWS = Slower walking speed.
doi:10.1371/journal.pone.0093511.t002
Table 3. Actual and accelerometer-measured steps taken and accelerometer accuracy in 63 persons with mild, moderate, and
severe MS.
Speed Disability Steps Taken
Percentage of Actual Steps Taken Measured by
Accelerometers
Actual ActiGraph StepWatch ActiGraph StepWatch
CWS Overall 591.0 (97.2) 575.6 (116.0) 589.6 (102.6) 97.4% 99.8%
Mild 641.0 (54.4) 639.8 (59.0) 640.4 (58.8) 99.8% 99.9%
Moderate 634.0 (54.4) 629.0 (62.6) 645.6 (56.4) 99.2% 101.8%
Severe 484.8 (91.4) 440.6 (100.0) 478.4 (99.2) 90.9% 98.7%
FWS Overall 645.8 (103.8) 617.4 (126.6) 645.2 (101.6) 95.6% 99.9%
Mild 698.8 (58.2) 698.6 (63.6) 696.2 (58.0) 100.0% 99.6%
Moderate 690.0 (52.4) 684.0 (58.8) 690.8 (53.8) 99.1% 100.1%
Severe 529.0 (102.4) 480.8 (118.0) 534.0 (97.6) 90.9% 100.9%
SWS Overall 520.6 (107.4) 497.0 (132.4) 515.6 (119.0) 95.5% 99.0%
Mild 572.2 (64.8) 574.6 (68.0) 572.0 (68.0) 100.4% 100.0%
Moderate 573.8 (55.8) 549.4 (81.8) 574.2 (56.6) 95.7% 100.1%
Severe 400.0 (95.6) 349.2 (116.4) 382.6 (114.0) 87.3% 95.7%
Note: Data are presented as mean (SD); CWS = Comfortable walking speed; FWS = Faster walking speed; SWS = Slower walking speed.
doi:10.1371/journal.pone.0093511.t003
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MS. All participants were able to complete each 6MW test without
incident, including those with severe disability. This is consistent
with seminal research involving the administration and tolerability
of three maximal 6MW tests in persons with mild, moderate, and
severe MS [13]. The current approach further was successful in
the manipulation of walking speed across the three levels of
disability status. The primary novel findings were that under the
CWS and FWS conditions of the 6MW, both the ActiGraph
model GT3X+ accelerometer (95.6%–97.4%; i.e., 4.4%–2.6%
underestimation of steps) and StepWatch activity monitor (99.8%–
99.9%; i.e., 0.2%–0.1% underestimation of steps) demonstrated
highly accurate measurement of actual steps taken. As the CWS
condition involved a self-selected pace, and presumably is the most
common walking pace at which free-living ambulation occurs, the
current accuracy results would support the use of either device in
clinical research applications for measuring free-living steps/day in
persons with MS. However, under the SWS condition of the 6MW
(i.e., 0.5 mph slower than CWS), it is of note that the StepWatch
measured a greater percentage of actual steps taken (99.0%) than
the ActiGraph (95.5%) in the overall sample, and this was
particularly apparent in those with severe disability (StepWatch:
95.7%; ActiGraph: 87.3%). This inaccuracy further was observed
in persons who were classified as ‘most limited community walkers’
under SWS conditions. This slight inaccuracy in measurement for
the ActiGraph might be attributed to altered spatiotemporal
parameters of gait (i.e., slower velocity, shorter step length, longer
step time, wider base of support, and more time spent in double
support of the gait cycle) and greater perceived impact of walking
impairment. Perhaps the ActiGraph device is not sensitive enough
for capturing bodily displacement during slow walking speed
among those with severe disability characterized by altered gait.
Importantly, previous studies of the accuracy in measurement of
these motion sensors were unable to capture potential walking and
gait-related sources of error, as such studies have been limited in
sample size and only included persons with a narrow range of MS
disability [4,11]. One study reported that the ActiGraph model
7164 accelerometer (a precursor to the model GT3X+) accurately
measured steps taken in persons with mild MS while walking at
2.0 mph (95.1%), 2.5 mph (99.8%), and 3.0 mph (99.7%) on a
motor-driven treadmill, respectively [4]. The current results are
consistent with those values in persons with mild MS (measure-
ment of 100.4% of steps taken for SWS (i.e., 0.4% overestimation);
99.8% of steps taken for CWS (i.e., 0.2% underestimation); and
100.0% of steps taken for FWS), and extend results from that
previous investigation by providing accuracy measurements in
individuals with moderate and severe MS disability. The current
accuracy results for the StepWatch are consistent with a previous
study that reported 98.1% accuracy for the StepWatch during
3.87 m of comfortable walking in 9 women with moderate MS
disability [11]. We report that under CWS conditions for a longer
duration of time (i.e., 6 minutes), the StepWatch measured
101.8% of steps taken (i.e., 1.8% overestimation) in persons with
moderate MS disability, and similarly accurate measurement of
steps taken in persons with mild (99.9%; i.e., 0.1% underestima-
tion) and severe (98.7%; i.e., 1.3% underestimation) disability.
Collectively, this has potential implications for the interpretation of
results from previous investigations using the ActiGraph GT3X+
as a measure of steps/day, such that this accelerometer might be
underestimating steps during slow walking speeds, particularly in
individuals with severe disability who have altered gait kinematics.
For example, one recent study reported that persons with MS take
an average of 5,826 steps/day based on step counts from
ActiGraph accelerometers [5]. Those results should be interpreted
with caution, such that persons with MS might actually be
participating in slightly more physical activity, based on the
potential underestimation of steps/day by the ActiGraph model
GT3X+.
The current results have potential implications for future
research. Importantly, the current over-ground walking protocol
was conducted under highly-controlled laboratory conditions and
represents an intermediary condition between the treadmill and
real world (i.e., this reflects the progression of confirmation before
testing under real-world conditions). The overall accuracy in
measurement of the ActiGraph and StepWatch under CWS and
FWS conditions supports the inclusion of either unit in future
clinical research in persons with MS examining steps/day as a
free-living measure of ambulation. The StepWatch did demon-
strate slightly better accuracy than the ActiGraph overall, although
this difference in accuracy was minimal across different speeds,
based on a non-significant speed6device interaction. Though
these differences were negligible in persons with mild and
moderate MS disability, and during CWS and FWS conditions,
there was a slight reduction in accuracy for both motion sensors
during SWS, particularly among persons with severe MS
disability. There was a greater discrepancy in accuracy during
SWS across devices in persons with severe disability such that the
StepWatch still measured 95.7% of steps taken (i.e., 4.3%
underestimation), whereas the ActiGraph accurately measured
87.3% of steps taken (i.e., 12.7% underestimation), although this
interaction was not statistically significant. This discrepancy would
seemingly favor the StepWatch over the ActiGraph GT3X+ for
measuring steps in clinical samples with severe disability, though it
is unclear if this difference is sufficient to overwhelmingly favor the
StepWatch over the ActiGraph GT3X+.
Though the StepWatch demonstrated greater accuracy than the
ActiGraph model GT3X+ overall, it comes at somewhat of a cost,
possibly limiting the utility of this device. The StepWatch activity
monitor only measures step counts and step rates as measures of
ambulatory physical activity; this device cannot express a
quantification of the body’s positive and negative accelerations
(i.e., activity counts) to provide information about the intensity of
short bouts of physical activity, whereas the ActiGraph model
GT3X+ is capable of quantifying such accelerations as activity
counts. This is important for understanding whether or not
persons with MS are meeting public health guidelines for physical
activity (i.e., 150 minutes per week of moderate-to-vigorous
physical activity). The StepWatch is not as commonly used as
ActiGraph accelerometers for measuring ambulatory physical
activity in persons with MS and the GT3X+ is the newest
commercially-available model, such that making comparisons
across different samples can be difficult [2]. Finally, although
highly accurate, the StepWatch is quite expensive compared with
the ActiGraph model GT3X+, and might be a less feasible option
for large-scale clinical research endeavors.
There were many strengths of the current study including the
inclusion of over-ground walking at 3 different speeds and a
relatively large sample of persons with varying MS disability, but it
is not without limitations. The two primary limitations of this study
were that we compared the accuracy of only 2 devices at only 3
different speeds. ActiGraph and StepWatch accelerometers
represent the two most commonly used accelerometers for
measuring ambulation in healthy and disease populations,
including MS [10]. Further, it was practical to compare the
accuracy of these units as each is affixed to a different location on
the body during ambulation; there is likely a limit to the number of
accelerometers that can be simultaneously positioned on the same
bodily location without influencing accuracy. Future research
might examine the accuracy of other types of motion sensors (e.g.,
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Actical, TriTac accelerometers) for measuring steps under a
broader range of walking speeds to better quantify the scope of
accuracy in measurement for each device. Another limitation
includes the dual-task effect of having the participants follow a
researcher during FWS and SWS conditions. We recognize that
based on this, the current values for 6MW are not comparable to
those from studies that use a standard 6MW protocol [13]. As
such, the reported values for 6MW distance, especially under FWS
and SWS conditions, should be interpreted with caution, though
this was not a primary outcome of the current study. There was a
high proportion of persons with relapsing-remitting MS, despite
the stratification of participants into EDSS groups of mild,
moderate, and severe disability. A final limitation is that we did
not measure the accuracy of each motion sensor during running.
We were not interested in this modality of physical activity, based
on the large range of MS disability, although it would be of interest
to researchers examining the full extent of accuracy in measure-
ment of the StepWatch activity monitor and the ActiGraph model
GT3X+.
Conclusions
Overall, we report that the ActiGraph model GT3X+ and
StepWatch activity monitor both demonstrate highly accurate
measurement of steps taken during comfortable and faster over-
ground walking. This supports the inclusion of both motion
sensors in clinical applications measuring steps/day. However,
future researchers should be aware of a slight discrepancy in
accuracy at slower walking speeds, particularly among those with
severe disability, such that the ActiGraph model GT3X+ might
underestimate steps taken by upwards of 10%. We believe that this
is an intermediary between treadmill and real-world conditions
that can help inform the choice on adopting accelerometers in
clinical trials of MS wherein the monitoring of free-living walking
behavior is of particular value.
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